IP Library Granted Patent US 9,783,781
Granted Patent B2
US 9,783,781 · App. 13/817,535 · Granted Oct 10, 2017

Methods of generating oligodendrocytes and cell populations comprising same

Inventors: Shimon Slavin (Tel-Aviv, IL); Chaya Brodie (Southfield, MI)
Assignee: EXOSTEM BIOTEC LTD.
C12N5/0622C12N15/113A61K35/12C12N2310/141C12N2320/30C12N2330/10C12N2500/25C12N2501/39C12N2501/65C12N2506/025C12N2506/1353C12N2506/1384C12N2506/1392
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,783,781
App. No.
13/817,535
Granted
Oct 10, 2017
Kind
B2
Abstract

A method of generating a population of cells useful for treating a brain disorder in a subject is disclosed. The method comprises contacting mesenchymal stem cells (MSCs) with at least one exogenous miRNA having a nucleic acid sequence at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 15-19 and 27-35, thereby generating the population of cells and/or generating neurotrophic factors that may provide important signals to damaged tissues or locally residing stem cells. MSCs differentiated by miRs may also secrete miRs and deliver them to adjacent cells and therefore provide important signals to neighboring endogenous normal or malignant cells.

Claims (4)

1. A method of treating a brain tumor in a subject in need thereof, the method comprising transplanting a therapeutically effective amount of mesenchymal stem cells which have been modified to express exogenous miRNA miR-124, wherein said mesenchymal stem cells deliver said exogenous miRNA to the cytosol of a cell of the tumor, thereby treating the brain tumor.

2. The method of claim 1 , wherein said brain tumor is a glioma.

3. The method of claim 1 , further comprising expressing in said mesenchymal stem cells a pro-apoptotic agent.

4. The method of claim 3 , wherein said pro-apoptotic agent comprises soluble TNF-related apoptosis-inducing ligand (sTRAIL).

Assignments (2)
CHANGE OF NAME Recorded Aug 23, 2017
From: BRAINSTEM BIOTEC LTD.
To: EXOSTEM BIOTEC LTD.
Reel/Frame 043373/0247 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2013
From: SLAVIN, SHIMON; BRODIE, CHAYA
To: BRAINSTEM BIOTEC LTD.
Reel/Frame 030463/0582 →
Continuity (3)
Provisional Application 61373909 · Aug 16, 2010
Provisional Application 61433301 · Jan 17, 2011
Related Publication 20130149288A1 · Jun 13, 2013